Methods of treating dyskinesia and related disorders
View Patent ↗The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.
1. A method of treating a dyskinesia in a human comprising administering to the human in need thereof an effective amount of sydnocarb, or a pharmaceutically acceptable salt thereof, and L-Dopa.
2. The method of claim 1 wherein the sydnocarb, or a pharmaceutically acceptable salt thereof, and L-Dopa are present within different pharmaceutical compositions.
3. The method of claim 2 wherein the pharmaceutical composition comprising sydnocarb, or a pharmaceutically acceptable salt thereof, is administered to the human prior to the pharmaceutical composition comprising L-Dopa.
4. The method of claim 2 wherein the pharmaceutical composition comprising sydnocarb, or a pharmaceutically acceptable salt thereof, is administered to the human subsequent to the pharmaceutical composition comprising L-Dopa.
5. The method of claim 2 wherein the pharmaceutical composition comprising sydnocarb, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition comprising L-Dopa are administered to the human concurrently.
6. The method of claim 2 wherein the pharmaceutical compositions are in the form of a tablet, pill, or capsule.
7. The method of claim 1 wherein the administration is oral.
8. The method of claim 1 wherein the dyskinesia is levodopa-induced dyskinesia, chronic or tardive dyskinesia, or orofacial dyskinesia.
9. The method of claim 1 wherein the levodopa-induced dyskinesia is off-period dystonia, diphasic dyskinesia, or peak-dose dyskinesia.
10. The method of claim 1 wherein the sydnocarb comprises the formula
or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R 1 is H and r is 1; R 2 and R 3 are H and n is 1; R 4 and R 5 are H and p is 1; R 7 is H; and R 8 is H.
11. A method of treating levodopa-induced dyskinesia in a human comprising orally administering to the human in need thereof a pharmaceutical composition in the form of a tablet, pill, or capsule comprising 0.01 mg to 70 mg per kg body weight of sydnocarb comprising the formula
or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R 1 is H and r is 1; R 2 and R 3 are H and n is 1; R 4 and R 5 are H and p is 1; R 7 is H; and R 8 is H;
and another pharmaceutical composition comprising L-Dopa.
12. A pharmaceutical composition comprising sydnocarb and L-Dopa.